ICPT

Intercept Pharmaceuticals

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$490.6M

Burn Rate (Qtr)

-$66.5M

Company Profile

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

OCALIVA® (obeticholic acid)

Primary Biliary Cholangitis (PBC)

Quarterly Sales (Approved)

February 26, 2021 (Est)

Ocaliva

Adult nonalcoholic steatohepatitis (NASH)

NDA Resubmission

2021

Ocaliva

Primary Sclerosing Cholangitis

TBD

Ocaliva

Biliary Atresia

Phase 2

TBD

Recent Posts

See what the community is saying - click to see full post

ITCI - Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update

ICPT - Intercept Pharmaceuticals Reports Third Quarter 2020 Financial Results, Announces Updates to Financial

ICPT - Type A Meeting held with FDA on NASH Fibrosis Program

ICPT - Q2 2020 Ocaliva Net Sales

Trilaciclib NDA Filing (GTHX)

ICPT CRL for Ocaliva

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon